

- **Name:** Sehhoon Park
 - **Current Position & Affiliation:** Clinical Assistant Professor, Samsung Medical Center, Division of Hematology and Medical Oncology
 - **Country:** Republic of Korea
-

- **Educational Background:**

- Mar. 2005- Feb. 2009 Seoul National University College of Medicine, Seoul, Korea
- Mar. 2014- Feb, 2016 Master of Science, Department in Clinical Medical Science, Seoul National University College of Medicine, Seoul, Korea
- Mar. 2018 –Aug, 2020 PhD. Degree, Graduate School of Medicine, Sungkyunkwan University, Seoul, Korea

- **Professional Experience:**

- Mar. 2011- Feb. 2012: Internship, Seoul National University Hospital, Seoul, Korea
- Mar. 2012- Feb. 2016: Residency Course at Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- Jun. 2016- Nov. 2017: Country Medical Lead, Medical Affairs, Roche Korea
- Dec. 2017- Nov. 2019: Clinical Fellow, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.
- Dec. 2019 – Current: Clinical assistant professor, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Seoul, South Korea.

- **Professional Organizations:**

- Feb. 2012- Present: Korean Association of Internal Medicine, Member
- Mar. 2014- Present: Korean Cancer Association, Associate Member
- Mar. 2014- Present: Korean Association for Clinical Oncology, Associate Member
- Mar. 2014- Present: American Society of Clinical Oncology, Member in training
- Dec 2014- Present: American Association for Cancer Research, Associate Member

- **Main Scientific Publications:**

1. Seong M, **Park S**, Kim ST, Park SG, Kim YK, Kim H-J, et al. Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. *Journal of Neuro-Oncology*. 2020;149(2):367-72.
2. **Park S**, Shim J, Mortimer PG, Smith SA, Godin RE, Hollingsworth SJ, et al. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. *Cancer*. 2020;126(17):4002-12.
3. **Park S**, Lee M-H, Seong M, Kim S, Kang J-H, Cho B, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. *Annals of Oncology*. 2020;31(10):1397-404.
4. **Park S**, Lee E, Park S, Lee S, Nam SJ, Kim SW, et al. Clinical characteristics and exploratory

- genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. *Molecular Cancer Research*. 2020;18(9):1315-25.
5. **Park S**, Ku BM, Jung HA, Sun J-M, Ahn JS, Lee S-H, et al. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation. *Cancer Research and Treatment: Official Journal of Korean Cancer Association*. 2020;52(4):1288.
 6. **Park S**, Shim JH, Lee B, Cho I, Park W-Y, Kim Y, et al. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. *Lung Cancer*. 2019;134:7-15.
 7. **Park S**, Lee S-H, Park K. In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer*. 2019;14(12):e279-e80.
 8. **Park S**, Lee H, Lee B, Lee S-H, Sun J-M, Park W-Y, et al. DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC. *Journal of Thoracic Oncology*. 2019;14(9):1640-50.
 9. **Park S**, Lee E, Park S, Lee S, Hur JY, Yoon SE, et al. Clinical characteristics and combined somatic mutation using target sequencing among breast cancer patients with germline BRCA mutation. *AACR*; 2019.
 10. **Park S**, Joung J-G, Min YW, Nam J-Y, Ryu D, Oh D, et al. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. *Journal for immunotherapy of cancer*. 2019;7(1):1-14.
 11. **Park S**, Han J, Sun J-M. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. *Lung Cancer*. 2019;127:66-8.